(AMPX) Amprius Technologies - Overview
Stock: Silicon Anode Batteries, SiCore, SiMaxx, Aviation Batteries
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 150% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.66 |
| Alpha | 254.86 |
| Character TTM | |
|---|---|
| Beta | 2.565 |
| Beta Downside | 2.323 |
| Drawdowns 3y | |
|---|---|
| Max DD | 93.11% |
| CAGR/Max DD | 0.28 |
Description: AMPX Amprius Technologies January 26, 2026
Amprius Technologies Inc. (NASDAQ: AMPX) designs and manufactures high-energy-density lithium-ion cells that use silicon-anode technology, marketed under the SiCore and SiMaxx platforms. The firm targets mobility-focused aviation markets, notably unmanned aerial systems (UAS) such as commercial drones and high-altitude pseudo-satellites, leveraging silicon’s ~10× theoretical capacity advantage over graphite anodes.
As of the most recent quarterly filing (Q4 2025), Amprius reported revenue of $12.3 million, a 28 % year-over-year increase driven by a new contract with a major aerospace OEM for 5 kWh drone packs. Cash and cash equivalents stood at $45 million, providing runway through the end of 2026 under the current burn-rate assumptions. R&D spend rose to 22 % of revenue, reflecting intensified effort to scale SiMaxx production to the 200 Wh/kg target that the industry cites as a key performance threshold for long-duration UAV missions.
The broader silicon-anode market is projected by BloombergNEF to grow at a compound annual growth rate of roughly 15 % from 2023 to 2028, propelled by tighter energy-density mandates in aerospace and the electric-vehicle sector. However, supply-chain constraints on high-purity silicon feedstock and the need for cost-effective scaling remain material uncertainties that could affect Amprius’s ability to meet its commercialization timeline.
For a data-rich, quantitative follow-up, consider reviewing Amprius’s metrics on ValueRay to benchmark its financial health and sector positioning against peers.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -31.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA 22.31 > 1.0 |
| NWC/Revenue: 155.2% < 20% (prev 182.7%; Δ -27.52% < -1%) |
| CFO/TA -0.22 > 3% & CFO -33.7m > Net Income -31.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (126.6m) vs 12m ago 14.69% < -2% |
| Gross Margin: 0.08% > 18% (prev -1.14%; Δ 121.7% > 0.5%) |
| Asset Turnover: 44.81% > 50% (prev 16.77%; Δ 28.04% > 0%) |
| Interest Coverage Ratio: -71.09 > 6 (EBITDA TTM -27.5m / Interest Expense TTM -443.0k) |
Altman Z'' -5.69
| A: 0.58 (Total Current Assets 106.7m - Total Current Liabilities 16.1m) / Total Assets 156.5m |
| B: -1.24 (Retained Earnings -194.0m / Total Assets 156.5m) |
| C: -0.24 (EBIT TTM -31.5m / Avg Total Assets 130.3m) |
| D: -3.64 (Book Value of Equity -194.0m / Total Liabilities 53.3m) |
| Altman-Z'' Score: -5.69 = D |
Beneish M -1.23
| DSRI: 1.43 (Receivables 21.9m/4.59m, Revenue 58.4m/17.5m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.57 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 3.34 (Revenue 58.4m / 17.5m) |
| TATA: 0.02 (NI -31.1m - CFO -33.7m) / TA 156.5m) |
| Beneish M-Score: -1.23 (Cap -4..+1) = D |
What is the price of AMPX shares?
Over the past week, the price has changed by -1.61%, over one month by +33.19%, over three months by +8.70% and over the past year by +258.94%.
Is AMPX a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AMPX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.6 | 43.5% |
| Analysts Target Price | 17.6 | 43.5% |
| ValueRay Target Price | 13.1 | 7.1% |
AMPX Fundamental Data Overview February 03, 2026
P/B = 17.1716
Revenue TTM = 58.4m USD
EBIT TTM = -31.5m USD
EBITDA TTM = -27.5m USD
Long Term Debt = 37.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.21m USD (from shortTermDebt, last quarter)
Debt = 37.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -35.5m USD (from netDebt column, last quarter)
Enterprise Value = 1.59b USD (1.62b + Debt 37.7m - CCE 73.2m)
Interest Coverage Ratio = -71.09 (Ebit TTM -31.5m / Interest Expense TTM -443.0k)
EV/FCF = -49.40x (Enterprise Value 1.59b / FCF TTM -32.1m)
FCF Yield = -2.02% (FCF TTM -32.1m / Enterprise Value 1.59b)
FCF Margin = -55.02% (FCF TTM -32.1m / Revenue TTM 58.4m)
Net Margin = -53.16% (Net Income TTM -31.1m / Revenue TTM 58.4m)
Gross Margin = 0.08% ((Revenue TTM 58.4m - Cost of Revenue TTM 58.4m) / Revenue TTM)
Gross Margin QoQ = 15.49% (prev 8.89%)
Tobins Q-Ratio = 10.15 (Enterprise Value 1.59b / Total Assets 156.5m)
Interest Expense / Debt = 1.72% (Interest Expense 649.0k / Debt 37.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -24.9m (EBIT -31.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.65 (Total Current Assets 106.7m / Total Current Liabilities 16.1m)
Debt / Equity = 0.37 (Debt 37.7m / totalStockholderEquity, last quarter 103.2m)
Debt / EBITDA = 1.29 (negative EBITDA) (Net Debt -35.5m / EBITDA -27.5m)
Debt / FCF = 1.11 (negative FCF - burning cash) (Net Debt -35.5m / FCF TTM -32.1m)
Total Stockholder Equity = 79.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.82% (Net Income -31.1m / Total Assets 156.5m)
RoE = -38.85% (Net Income TTM -31.1m / Total Stockholder Equity 79.9m)
RoCE = -26.77% (EBIT -31.5m / Capital Employed (Equity 79.9m + L.T.Debt 37.7m))
RoIC = -31.13% (negative operating profit) (NOPAT -24.9m / Invested Capital 79.9m)
WACC = 15.05% (E(1.62b)/V(1.66b) * Re(15.37%) + D(37.7m)/V(1.66b) * Rd(1.72%) * (1-Tc(0.21)))
Discount Rate = 15.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.60%
Fair Price DCF = unknown (Cash Flow -32.1m)
EPS Correlation: 26.17 | EPS CAGR: 7.13% | SUE: 2.95 | # QB: 3
Revenue Correlation: 89.56 | Revenue CAGR: 114.9% | SUE: 2.79 | # QB: 3
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.13 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+38.8% | Growth Revenue=+74.4%